Table 11.

Percentage of Pathogens Reported from Adult Central Line-Associated Bloodstream Infections^a (CLABSIs) that Tested Nonsusceptible^b (NS) to Selected Antimicrobial Agents, by Location Type,^c 2015–2017

Pathogen, Antimicrobial	Hospital Wardsc			Hospital ICUs			Hospital Oncology Units			LTACHs
	No. Reported	% Tested	% NSb	No. Reported	% Tested	% NSb	No. Reported	% Tested	% NSb	No. Reported	% Tested	% NSb
Staphylococcus aureus	5,386			2,497			1,163			1,217
OX/CEFOX/METH (MRSA)		91.0	53.8		90.7	50.0*		91.2	45.8*		96.5	77.6*
Enterococcus faecium	1,673			1,981			1,670			691
Vancomycin (VRE)		94.9	78.3		94.5	84.5*		94.5	81.6*		98.3	84.4*
Enterococcus faecalis	2,636			2,117			664			1,314
Vancomycin (VRE)		93.6	10.7		93.0	8.5*		89.9	7.4*		95.4	18.0*
Selected Klebsiella spp	3,344			1,708			1,441			1,158
ESCs		81.9	25.2		83.0	29.6*		85.5	19.7*		92.3	49.6*
Carbapenems (CRE)		74.9	8.4		76.9	11.0*		73.6	4.9*		88.3	24.7*
MDR		90.9	15.7		90.5	20.2*		91.8	12.5*		97.8	40.0*
Escherichia coli	2,279			1,129			2,667			394
ESCs		81.7	27.4		82.2	29.8		84.7	28.3		89.3	40.3*
Carbapenems (CRE)		74.6	1.2		73.9	2.4*		76.6	1.4		87.6	2.3
FQs		91.8	47.1		90.4	43.2*		90.3	65.3*		96.2	60.2*
MDR		91.0	14.1		88.8	14.4		90.1	17.6*		94.7	26.3*
Enterobacter spp	1,453			1,078			532			383
Cefepime		74.2	10.5		74.5	12.2		77.6	10.9		77.0	17.3*
Carbapenems (CRE)		80.2	4.7		76.2	7.2*		78.0	7.2		86.2	9.4*
MDR-2		91.5	6.2		89.6	7.7		90.0	7.1		95.6	13.7*
Pseudomonas aeruginosa	1,407			1,061			701			495
AMINOs		93.3	12.8		90.9	14.9		92.6	8.9*		96.2	23.5*
ESCs-2		92.0	21.9		90.2	26.5*		91.2	15.2*		94.9	37.7*
FQs-2		92.0	23.5		89.8	27.1		91.9	22.5		96.4	41.9*
Carbapenems-2		80.0	19.8		77.5	26.3*		81.9	19.2		88.7	37.4*
PIP/PIPTAZ		86.9	15.5		85.6	20.2*		88.2	12.5		87.7	29.3*
MDR-3		93.2	13.6		91.2	18.6*		92.4	11.6		97.2	29.9*
Acinetobacter spp	660			392			66			245
Carbapenems-2		78.8	33.1		80.6	47.2*		75.8	12.0*		86.1	75.4*
MDR-4		94.1	34.6		92.6	46.6*		93.9	12.9*		99.6	76.6*

Note. ICUs, intensive care units; LTACHs, long-term acute-care hospitals; Selected Klebsiella spp, K. oxytoca and K. pneumoniae; OX/CEFOX/METH, oxacillin, cefoxitin, or methicillin; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus; ESCs, extended-spectrum cephalosporins (cefepime, cefotaxime, ceftazidime, or ceftriaxone); CRE, carbapenem-resistant Enterobacteriaceae (imipenem, meropenem, doripenem, or ertapenem); MDR, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs, FQs, AMINOs, carbapenems (R only), PIPTAZ); MDR-2, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: cefepime, FQs, AMINOs, carbapenems (R only), PIPTAZ); FQs: fluoroquinolones (ciprofloxacin, levofloxacin, or moxifloxacin); AMINOs, aminoglycosides (amikacin, gentamicin, or tobramycin); ESCs-2, extended-spectrum cephalosporins (cefepime or ceftazidime); FQs-2, fluoroquinolones (ciprofloxacin or levofloxacin); PIP, piperacillin; PIPTAZ, piperacillin/tazobactam; Carbapenems-2, imipenem, meropenem, or doripenem; MDR-3, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs-2, FQs-2, AMINOs, carbapenems-2, PIP/PIPTAZ); MDR-4, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs-2, FQs-2, AMINOs, carbapenems-2, PIP/PIPTAZ, ampicillin/sulbactam).

^*Statistically significantly different than %NS in hospital wards; P < .05.

^aSupplemental tables are available in the 2015–2017 Adult Antimicrobial Resistance Report Online Supplement that show the %NS separately for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) and non–MBI-LCBIs within hospital oncology locations (https://www.cdc.gov/nhsn/datastat/index.html).

^bMRSA, VRE, and CRE data are presented as %R (ie, includes only those pathogens that tested resistant). All other phenotypes are shown as %NS (ie, includes pathogens that tested intermediate or resistant).

^cLocation types are mutually exclusive. “Hospital wards” includes step-down units, mixed acuity units, and specialty care areas.